A federal appeals court has upheld the FDA’s determination that Ozempic, Wegovy, Mounjaro, and Zepbound are no longer in shortage, dealing a legal defeat to the compounding industry’s effort to preserve its ability to mass-produce copycat versions of the blockbuster GLP-1 drugs.
The U.S. Court of Appeals for the D.C. Circuit ruled that the FDA followed proper procedure when it declared the shortages over for Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound. The decision is a loss for the Outsourcing Facilities Association (OFA), which had challenged the agency’s determinations.
The ruling reinforces FDA authority over shortage declarations affecting compounded GLP-1 medications used by telehealth platforms and compounding pharmacies. With the shortage declarations upheld, compounding pharmacies and 503B outsourcing facilities lose the legal basis they had relied on to produce compounded semaglutide and tirzepatide at scale.
What happened
The FDA issued determinations that Ozempic, Wegovy, Mounjaro, and Zepbound were no longer in shortage, triggering requirements for compounding pharmacies and 503B outsourcing facilities to stop mass-producing compounded copies of those drugs. The Outsourcing Facilities Association challenged the FDA’s process, arguing the agency had not followed proper procedures in reaching its shortage-end determinations.
The D.C. Circuit rejected that challenge, finding that the FDA went through the proper process when it declared the drugs no longer in shortage. The court’s ruling upholds the FDA’s determinations and removes the legal foundation for the OFA’s challenge.
Why it matters
The court’s decision carries implications across several sectors:
- Compounding pharmacies and 503B outsourcing facilities have already been required to wind down production of compounded GLP-1 copies. This ruling removes the legal basis to challenge that requirement.
- Telehealth peptide platforms that have offered compounded semaglutide or tirzepatide face narrowed options as the legal pathway for mass-producing those compounds is closed.
- GLP-1 patients who have relied on compounded versions may see changes in availability and access as compounders exit the market for these specific drugs.
- The broader regulatory landscape may be affected: the ruling could signal judicial deference to the FDA on shortage determinations, potentially shaping how future challenges to agency decisions are handled.
The ruling also benefits Novo Nordisk and Eli Lilly by closing a legal avenue that had allowed compounders to produce copies of their branded GLP-1 drugs during the declared shortage period.
What to watch next
- Whether the Outsourcing Facilities Association seeks further appeal, including a potential petition for rehearing or review by a higher court.
- How compounding pharmacies and 503B facilities respond operationally, including whether any pivot to other compounded products or pursue alternative legal arguments.
- The impact on telehealth platforms that have built business models around compounded GLP-1 medications, including whether they adjust offerings or partnerships.
- Whether the ruling influences future FDA shortage declarations and how compounders prepare for similar determinations involving other drugs.
Sources
Industry information only. Not medical or legal advice.
